Arndt Vogel

RATIONALE-301: elderly subgroup analysis of tislelizumab in HCC 3:14
RATIONALE-301: elderly subgroup analysis of tislelizumab in HCC
Arndt Vogel • 3 Jul 2023
The role of the PLATON Network in enhancing precision oncology 2:17
The role of the PLATON Network in enhancing precision oncology
Arndt Vogel • 3 Jul 2023
Analysis of the European/North American subgroup in the RATIONALE-301 trial 0:39
Analysis of the European/North American subgroup in the RATIONALE-301 trial
Arndt Vogel • 3 Jul 2023
Advances in FGFR inhibition for hepatobiliary cancer 2:27
Advances in FGFR inhibition for hepatobiliary cancer
Arndt Vogel • 3 Jul 2023
Final results from FIGHT-202: pemigatinib for patients with FGFR-mutated advanced cholangiocarcinoma 3:30
Final results from FIGHT-202: pemigatinib for patients with FGFR-mutated advanced cholangiocarcinoma
Arndt Vogel • 22 Jul 2022
Targeted therapies for cholangiocarcinoma 2:26
Targeted therapies for cholangiocarcinoma
Arndt Vogel • 22 Jul 2022
HIMALAYA: Does underlying liver function impact efficacy of tremelimumab plus durvalumab for HCC? 3:34
HIMALAYA: Does underlying liver function impact efficacy of tremelimumab plus durvalumab for HCC?
Arndt Vogel • 22 Jul 2022
KEYNOTE-224: Second-line pembrolizumab for advanced hepatocellular carcinoma 2:25
KEYNOTE-224: Second-line pembrolizumab for advanced hepatocellular carcinoma
Arndt Vogel • 22 Jul 2022
Improving outcomes in HCC with immunotherapy 1:56
Improving outcomes in HCC with immunotherapy
Arndt Vogel • 11 Jun 2021
The rapid growth of FGFR2 inhibitors: pemigatinib in FIGHT-202 2:40
The rapid growth of FGFR2 inhibitors: pemigatinib in FIGHT-202
Arndt Vogel • 11 Jun 2021
The IMMULAB trial: pembrolizumab with local ablation for patients with early-stage HCC 1:25
The IMMULAB trial: pembrolizumab with local ablation for patients with early-stage HCC
Arndt Vogel • 11 Jun 2021
FIGHT-202: pemigatinib for FGFR2 altered CCA 2:40
FIGHT-202: pemigatinib for FGFR2 altered CCA
Arndt Vogel • 11 Jun 2021
Systemic therapies for advanced HCC 5:44
Systemic therapies for advanced HCC
Arndt Vogel • 9 Jul 2020
KEYNOTE-966: pembrolizumab, gemcitabine and cisplatin for CCA 3:39
KEYNOTE-966: pembrolizumab, gemcitabine and cisplatin for CCA
Arndt Vogel • 9 Jul 2020
FIGHT-202 data: pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma 2:14
FIGHT-202 data: pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma
Arndt Vogel • 29 Sep 2019
Moving beyond monotherapy in HCC 3:40
Moving beyond monotherapy in HCC
Arndt Vogel
The content of VJOncology is intended for healthcare professionals